Relapse-free survival does not differ significantly between those receiving pentostatin as initial induction, compared with those crossed over from interferon therapy (

P = .57). Figure shows estimated distributions of relapse-free survival (Kaplan-Meier estimates) from date of complete response, by phase of treatment. Tick marks indicate patients who were alive without report of relapse at last contact.